<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686344</url>
  </required_header>
  <id_info>
    <org_study_id>MS-383-2020</org_study_id>
    <nct_id>NCT04686344</nct_id>
  </id_info>
  <brief_title>Point of Care Optic Nerve Sheath Ultrasound to Assess Intracranial Pressure</brief_title>
  <official_title>Sonography of the Optic Nerve Sheath Diameter for Comparison Between the Effects of Continuous Infusion of 3%Hypertonic Saline With Intermittent Boluses Versus in Patients With Traumatic Brain Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated intracranial pressure (ICP) is one of the most common symptoms encountered in a&#xD;
      variety of traumatic injuries and diseases. Any tissue swelling within the rigid confines of&#xD;
      the skull results in increased ICP, which may lead to life-threatening structural alterations&#xD;
      in the brain or cerebral blood flow, thus causing oxygen deprivation and ischemia in the&#xD;
      brain.&#xD;
&#xD;
      Methods for ICP monitoring can be divided into invasive and noninvasive approaches. In&#xD;
      fluid-based systems, external ventricular drainage (EVD) has been considered the gold&#xD;
      standard.&#xD;
&#xD;
      Clinicians have found several noninvasive methods that can be used as surrogates for invasive&#xD;
      methods for ICP measurement. The optic nerve, as part of the central nervous system, is&#xD;
      wrapped by the dural sheath. The optic nerve sheath (ONS) is the continuation of the&#xD;
      subarachnoid space at the optic nerve, and its tissues are connected with the subarachnoid&#xD;
      space. Thus, an increase in ICP results in a corresponding elevation of the ONS diameter&#xD;
      (ONSD).&#xD;
&#xD;
      Hypertonic solutions such as mannitol and hypertonic saline (HTS) are recommended early in&#xD;
      the management of ICH after severe TBI . They provide therapeutic benefit along with a wide&#xD;
      therapeutic margin. The most recent BTF guidelines stated &quot;although hyperosmolar therapy may&#xD;
      lower intracranial pressure, there was insufficient evidence about effects on clinical&#xD;
      outcomes to support a specific recommendation, or to support use of any specific hyperosmolar&#xD;
      agent&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter of Optic nerve sheath</measure>
    <time_frame>UP TO 48 HOURS</time_frame>
    <description>assessment tool for Intracranial pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intracranial pressure</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Rebound increase intracranial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of Conscious</measure>
    <time_frame>UP TO 30 DAY</time_frame>
    <description>Glasgow Coma Score : A person's GCS score can range from 3 (completely unresponsive) to 15 (responsive).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Optic Nerve Sheath</condition>
  <condition>Hypertonic Saline</condition>
  <arm_group>
    <arm_group_label>Hypertonic saline continuous infusion Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive Hypertonic saline continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline intermittent boluses Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive Hypertonic saline intermittent boluses for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intermittent boluses of Hypertonic saline</intervention_name>
    <description>intermittent boluses every 6 hours over 30 min for 48 hours</description>
    <arm_group_label>Hypertonic saline intermittent boluses Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous infusion of Hypertonic saline</intervention_name>
    <description>continuous infusion over a period of 48 hours</description>
    <arm_group_label>Hypertonic saline continuous infusion Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who having Isolated traumatized brain injury (not for surgical intervention)&#xD;
&#xD;
          2. 3&lt;GCS ≤ 12.&#xD;
&#xD;
          3. Both genders.&#xD;
&#xD;
          4. Age ≥ 18 and ≤ 60Years.&#xD;
&#xD;
          5. Physical status ASA I - III.&#xD;
&#xD;
          6. Cut off value for optic nerve sheath diameter (ONSD) as 5.5 mm to diagnose increase in&#xD;
             ICP&gt; 20 mm Hg.&#xD;
&#xD;
        2. Exclusion criteria&#xD;
&#xD;
          1. Patients' first-degree relatives' refusal to sign the consent.&#xD;
&#xD;
          2. GCS (Glasgow coma score) &gt;12 or GCS of 3.&#xD;
&#xD;
          3. Contraindication to hypertonic saline: pregnancy, coagulopathy and cardiac&#xD;
             dysfunction.&#xD;
&#xD;
          4. Spinal cord injury, orbital injury, optic nerve injury and optic neuritis.&#xD;
&#xD;
          5. Multi organ affection.&#xD;
&#xD;
          6. Serum Na level ≥ 150 mmol/L at admission to ICU.&#xD;
&#xD;
          7. Hypotension requiring vasopressors to maintain MAP above 60 mmHg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo university</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Cairo University.</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Samir Wahdan</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, Pain management and Surgical ICU</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

